Abstract:Tracy E Madsen, 1, 2 Talia Sobel, 3 Seraphina Negash, 2 Tara Shrout Allen, 4 Marcia L Stefanick, 5 JoAnn E Manson, 6 Matthew Allison 7 1 Department of Emergency Medicine, Alpert Medical School of Brown University, Providence, RI, USA; 2 Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA; 3 Division of Women's Health Internal Medicine, Mayo Clinic Arizona, Scottsdale, AZ, USA; 4 Division of Preventive Medicine, University of California San Diego, San Diego, CA, USA; 5 Department of Medicine, Stanford University, Stanford, CA, USA; 6 Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; 7 Department of Family Medicine, University of California San Diego, San Diego, CA, USA Correspondence: Tracy E Madsen, Email Understanding the role of both menopausal hormone therapy (MHT) along with non-hormonal options for the treatment of vasomotor symptoms, sleep disruption, and genitourinary symptoms after menopause is critical to the health of women during middle and later life. Recent updates to the evidence for the treatment of menopausal symptoms pertaining to both hormonal and non-hormonal therapies as well as updated guidance from specialty societies can help guide clinicians in their treatment of women going through natural menopause or with estrogen deficiencies due to primary ovarian insufficiency or induced menopause from surgery or medications. The objective of this narrative review is to provide clinicians with an overview of MHT for the use of menopausal symptoms in women, incorporating updated primary evidence for risk versus benefit profiles, recent specialty society recommendations, and alternative, non-hormonal options. In this review, we summarize literature on the use of MHT for menopause-related symptomatology including options for formulations and dosages of MHT, non-hormonal treatment options, and the risk–benefit profile of MHT including long-term health consequences (eg, cardiovascular disease, cognitive decline, venous thromboembolism, and fracture risk). Finally, we highlight areas in which future research is needed to advance care of women after menopause. In summary, both hormonal (MHT) and non-hormonal options exist to treat symptoms of menopause. There is strong evidence for safety and effectiveness of MHT for the treatment of vasomotor symptoms among women who are less than 60 years of age, less than 10 years since menopause, and without significant cardiometabolic comorbidities. For others, treatment with hormonal versus non-hormonal therapies can be considered based on individual risk profiles, as well as other factors such as drug formulation, therapeutic goals, and symptom severity. Keywords: menopause, hormone therapy, cardiovascular disease, stroke Understanding the use of exogenous hormones for the treatment of menopausal symptoms (ie, menopausal hormone therapy (MHT)) 1 is of critical importance to the health of women, especially given that women spend approximately 40% of their lives post-menopause. 2 Postmenopausal symptoms that can be treated with MHT include vasomotor symptoms (VMS) (eg, hot flashes, night sweats), sleep disturbances, sexual dysfunction, and genitourinary tract symptoms (eg, vulvovaginal atrophy, dyspareunia, urinary frequency). 2 In addition to the treatment of menopausal symptoms, MHT may improve bone health among women after menopause, especially those with osteopenia or elevated risk of fracture. 3 Notably, the temporal patterns of utilization of MHT have changed. Specifically, between the late 1980s and early 2000s, the rate of MHT use decreased precipitously following the publication of results from the Women's Health Initiative (WHI) hormone clinical trials demonstrating an increased risk of coronary heart disease (CHD) and stroke among those randomized to MHT. 4,5 Consequently, the rates of MHT use decreased from approximately 22% in 1999 to 5% in 2010 among women 40 years or older in the United States, 6 while other studies cite rates as low was 3%. 6,7 Despite the rapid decline in utilization of MHT after the turn of the century, more recent recommendations 3,8 based on additional evidence have further clarified the subgroups of women in whom the benefits of MHT for VMS and bone health exceed the risks. Given the current evidence base on the likely benefit of MHT in specific subgroups of women, a recent increased focus on outcomes such as cognitive function, and the continued emergence of non-hormonal options for treating symptoms of menopause, the objective of this narrative review is to provide clinicians with an overview of MHT and alte -Abstract Truncated-

Hormone therapy: evolving concepts

A Contemporary View of Menopausal Hormone Therapy

Safety and benefit considerations for menopausal hormone therapy

From cardiovascular protection to cardiovascular risk: the metamorphosis of menopausal hormone therapy

Evolving issues in the clinical and managed care settings on the management of menopause following the women's health initiative

Risks, Benefits, and Treatment Modalities of Menopausal Hormone Therapy: Current Concepts

Menopausal hormone therapy and coronary heart disease: the roller-coaster history

A Review of Hormone and Non-Hormonal Therapy Options for the Treatment of Menopause

[Hormone therapy in menopause. A current update]

National use of postmenopausal hormone therapy: annual trends and response to recent evidence

Update on hormone therapy for the management of postmenopausal women

Alpha-2 adrenergic receptor localization in the rat heart and kidney using autoradiography and tritiated rauwolscine.

Long term hormone therapy for perimenopausal and postmenopausal women

Neutrophil-to-lymphocyte ratio is effective prognostic indicator for post-amputation patients with critical limb ischemia

Menopausal Symptoms in Older Women and the Effects of Treatment with Hormone Therapy

Cardiovascular risk in menopausal women and our evolving understanding of menopausal hormone therapy: risks, benefits, and current guidelines for use

Menopausal hormone therapy and women’s health: An umbrella review

Changes in the Use of Postmenopausal Hormone Therapy after the Publication of Clinical Trial Results

Menopausal Hormone Therapy: a Comprehensive Review

The use of menopausal hormone therapy after cancer

ATP-Binding Cassette Transporter A1 Modulates Apolipoprotein A-I Transcytosis Through Aortic Endothelial Cells